Podcasts about Mantle cell lymphoma

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCLECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCLCADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLLInMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FLSHR2554: Oral EZH2 Inhibitor in R/R PTCLSYRUS: AZD0486 Bispecific Antibody for R/R B-ALLPresenters:Max S. Topp, MDHead of Hematology and Clinical CAR-T Program LeadAssociated ProfessorMedinische Klinik und Poliklinkik IIUniversity of WurzburgWurzburg, GermanyPier Luigi Zinzani, MD, PhDProfessor of HematologyAlma Mater Studiorum- University of BolognaHead, “Seràgnoli” Institute of HematologyIRCCS Azienda Ospedaliero-Universitaria di BolognaDepartment of Medical and Surgical SciencesBologna University School of MedicineBologna, ItalyLink to full program:https://bit.ly/4obcJPI

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TZE865. CME credit will be available until July 22, 2026.Upfront Upgrades for Mantle Cell Lymphoma: Integrating the First-Line Use of BTKi Strategies Across Patient Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

In this episode, Associate Editor Dr. Philippe Armand discusses the Review Series on mantle cell lymphoma with author Dr. Christine Ryan. Both were authors of "Frontline management of mantle cell lymphoma", and discuss shifts in treatments and new research.Find the full review series in Volume 145 Issue 7 of Blood: "Review series on mantle cell lymphoma: sands shifting in the darkness"

Featuring perspectives from Dr Christopher Flowers, Dr Manali Kamdar, Ms Robin Klebig and Ms Caitlin Murphy, including the following topics: Introduction: Overview of Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma (0:00) Current and Future Use of Bruton Tyrosine Kinase Inhibitors for Mantle Cell Lymphoma (16:09) First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) (40:03) Role of Loncastuximab Tesirine for Patients with Relapsed/Refractory (R/R) DLBCL (57:31) Role of Tafasitamab for Patients with R/R DLBCL and Follicular Lymphoma (1:16:59) NCPD information and select publications

Featuring perspectives from Dr Stephen M Ansell and Dr Brian T Hill, including the following topics: Introduction: Bispecific Antibodies in Community Practice (0:00) Diffuse Large B-Cell Lymphoma (7:06) CD19, CD20 or Both? AZD0486 Bispecific Antibody (29:15) Mantle Cell Lymphoma (32:36) Follicular Lymphoma (48:08) CAR T-Cell Therapy for Marginal Zone Lymphoma (57:17) CME information and select publications

BTK inhibitors have transformed the treatment landscape in both frontline and relapsed/refractory (R/R) mantle cell lymphoma (MCL), offering a targeted... The post Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance appeared first on VJHemOnc.

In this week's episode we'll learn more about a phase 2 trial of first-line zanubrutinib, obinutuzumab, and venetoclax in TP53-mutated mantle cell lymphoma; early development of hyperdiploidy in multiple myeloma; and a phase 1 trial of the asparaginase pegcrisantaspase plus venetoclax in relapsed/refractory acute myeloid leukemia.Featured Articles:Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutationDevelopment of hyperdiploidy starts at an early age and takes a decade to completeA phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia

Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHCART24).

In this episode, we discussed the top abstracts in lymphoma and CLL presented at the ASH 2024 annual meeting in San Diego with Dr. David A Russler-Germain from Washington University. Here are the key abstracts we discussed: 1. 3 RCTs in Mantle Cell Lymphoma: a) Update on TRIANGLE: https://ash.confex.com/ash/2024/webprogram/Paper200735.htmlb) ENRICT Trial (Continuous Ibrutinib-Rituximab vs CIT [R-CHOP or BR]): https://ash.confex.com/ash/2024/webprogram/Paper199710.htmlc) ECOG-ACRIN EA4151 Trial (Auto-HCT vs Rituximab maintenance alone in patients with undetectable MRD after induction): https://ash.confex.com/ash/2024/webprogram/Paper212973.html2. DLBCL: a) Update on POLARIX Trial: https://ash.confex.com/ash/2024/webprogram/Paper197938.htmlb) Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in DLBCL Patients Receiving Polatuzumab Vedotin: https://ash.confex.com/ash/2024/webprogram/Paper202153.htmlc) COALITION trial: https://ash.confex.com/ash/2024/webprogram/Paper204930.html3. Follicular Lymphoma: a) Phase 3 inMIND trial (Tafasitamab + R2 vs Placebo + R2): https://ash.confex.com/ash/2024/webprogram/Paper212970.htmlb) Loncastuximab tesirine with rituximab in patients with R/R FL: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00345-4/abstract4. CLL: a) AMPLIFY Trial (Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy in 1st line CLL): https://ash.confex.com/ash/2024/webprogram/Paper200701.html5. Hodgkin Lymphoma: a) Pembrolizumab Maintenance Instead of Auto-HCT for R/R HL: https://ash.confex.com/ash/2024/webprogram/Paper202537.html

(Disclaimer: This episode contains advice on nutrition and lifestyle. Always consult your health care team regarding your personal circumstances).In this episode, we speak with Terena from Tampa, Florida, about her journey with CAR T-cell therapy, covering her experiences from diagnosis through recovery and remission. Diagnosed with mantle cell lymphoma, a type of non-Hodgkin's lymphoma, in September 2019, Terena endured years of misdiagnosis as her initial symptoms, such as severe hot flashes and night sweats, were attributed to menopause. It wasn't until a bone marrow biopsy that she was correctly diagnosed.Following her diagnosis, Terena underwent extensive testing, including specialized genetic tests like FoundationOne Heme and clonoSEQ, which helped tailor her treatment plan. She started on a combination therapy of Revlimid and rituximab before transitioning to CAR T-cell therapy in December 2020. She shares how the preparation for CAR T involved rigorous health screenings, including mental health assessments and apheresis, to collect her T cells.Terena details the intensive hospital stay during CAR T, where she faced several challenging side effects like cytokine release syndrome, neurotoxicity, and significant weight loss due to radiation-induced nausea. Despite these challenges, she avoided some severe complications such as seizures or viral reactivations, thanks to preemptive treatments and vigilant care. Her remission came three months post-treatment, a milestone that was both a relief and a testament to the effectiveness of the therapy.The cost of CAR T therapy was staggering, with an itemized hospital bill exceeding a million dollars. Fortunately, her insurance (including Medicare) covered a significant portion, though she emphasizes the importance of being financially prepared for such high medical expenses.Post-remission, Terena has made significant lifestyle changes to support her health. She follows a strict anti-inflammatory diet, avoiding GMOs, processed foods, and conventional dairy and meat products. She shares her regimen of juicing, incorporating nutrient-rich foods like organic berries, avocados, and cruciferous vegetables. Additionally, she has overhauled her home environment, switching to non-toxic cleaning products and cosmetics, using water and air filters, and incorporating wellness practices like infrared sauna therapy and regular exercise.Terena's commitment to reducing environmental toxins extends to every aspect of her life. She no longer uses products with harmful chemicals, such as nail polish or hair dye, and relies on digital tools to evaluate the safety of her food and personal care products. Her integrative health approach, combining conventional and holistic practices, plays a crucial role in maintaining her well-being.Her story is not only about overcoming physical challenges but also about the emotional and logistical aspects of undergoing such intensive treatment. From pre-paying bills and preparing meals in advance to relying on friends and family for transportation during her recovery, Terena's experience highlights the need for a strong support system. Her openness and detailed sharing of her journey are bound to help others navigating similar paths.Links: Gluten Free Scanner App: https://glutenfreescanner.app/EWG's "Clean Fifteen" List: https://www.ewg.org/foodnews/clean-fifteen.phpEWG's "Dirty Dozen" List: https://www.ewg.org/foodnews/full-list.phpFoundationOne Heme - foundationmedicine.comclonoSEQ - clonoseq.comThis season is made possible thanks to our sponsors:Kite, a Gilead company: http://www.kitepharma.com/and Bristol Myers Squibb's CAR T support services program:https://www.celltherapy360.com/ Follow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/Or visit our website at https://www.nbmtlink.org/

Featuring perspectives from Dr Tycel Phillips and Dr Michael Wang, including the following topics: Introduction: Interface Between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma (0:00) Key Datasets — Overview and First-Line Therapy (7:16) Faculty Case Presentations — Dr Phillips (27:03) Key Datasets — Relapsed/Refractory Disease (35:40) Faculty Case Presentations — Dr Wang (48:06) CME information and select publications  

Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma | Faculty Presentation — Michael Wang, MD CME information and select publications.

Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma.

Today's podcast focuses on the role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). You will... The post Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events appeared first on VJHemOnc.

Dr Tycel Phillips from the City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Michael Wang from the University of Texas MD Anderson Cancer Center in Houston discuss the current role of Bruton tyrosine kinase inhibitors for the management of newly diagnosed and relapsed/refractory mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/BTKInhibitorsMCL24).

In this episode, Tycel Phillips, MD joins Anthony and Bernie to discuss updates in Mantle Cell Lymphoma, including the TRIANGLE study and the recently published results of glofitamab in R/R MCL. TRIANGLE: https://pubmed.ncbi.nlm.nih.gov/38705160/ Glofitamab: https://pubmed.ncbi.nlm.nih.gov/39365960/

Staying abreast of recent clinical practice guidelines for the management of relapsed/refractory mantle cell lymphoma can be challenging for providers who may seldom encounter it in community practice. In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-based management of treatment-related adverse events can serve this patient population. “Fortunately, treatments such as BTK inhibitors are generally very well tolerated by patients, and there are very few patients who can't take a BTK inhibitor. But as you go up the scale of increasing intensity, such as CAR T-cell, or even allogeneic stem cell transplantation, those are therapies not suitable for patients with more extensive comorbidities.” – Dr. Jeff Sharman, MD   “A collaborative relationship between a community practice and an academic center can be of considerable benefit to a patient, so that as treatment decisions are made, both the physician and patient can feel like they're offering the patient the very best therapy.” – Dr. Jeff Sharman, MD    Jeff Sharman, MD  Medical Director of Hematology Research, US Oncology Director of Research Willamette Valley Cancer Institute Eugene, Oregon    This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy The CAR T-cell Therapy Process Patient-Caregiver CAR T-cell Therapy Facts Learn About CAR T-cell Therapy Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society

The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma.  “The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. “ –Dr. Nirav Shah, MD, MSHP   “We're not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it's going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy.” –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC Nirav Shah, MD, MSHP  Associate Professor of Medicine  Medical College of Wisconsin  Division of Hematology and Oncology  Milwaukee, Wisconsin    Kirollos Hanna, PharmD, BCPS, PCOP, FACCC  Assistant Professor of Pharmacy, Mayo Clinic  Director of Pharmacy  Minnesota Oncology   St. Paul, Minnesota    This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf   The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf   Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf   Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf    Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society  https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf   

CME credits: 1.00 Valid until: 24-09-2025 Claim your CME credit at https://reachmd.com/programs/cme/noncovalent-btk-inhibitors-new-targeted-options-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma/24362/ This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, necessitating therapies that extend survival and improve quality of life. Noncovalent Bruton's tyrosine kinase inhibitors (ncBTKi) show promise in these cases, but clinicians need updated knowledge on their use, including response rates and management of associated toxicities. Additionally, the evolving landscape of B-cell lymphoma therapies complicates treatment choices, requiring expert guidance on individualized therapy selection and sequencing.=

The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma. “The key to all of this is good collaboration between the community and their affiliates… their partners and academics, or tertiary referral centers, to really engage… these patients in a collaborative format… it really takes a team, a village, to take care of complex mantle cell lymphoma patients. “ –Dr. Nirav Shah, MD, MSHP   “We're not really seeing a lot of CAR T-cell therapy move in the frontline setting just yet, while there are a lot of ongoing clinical trials… Really, right now, it's going to be the patient characteristic: how well they did on frontline therapy, access to care, affordability, institutional preparedness… that would potentially… allow your patient to receive CAR T-cell therapy.” –Kirollos Hanna, PharmD, BCPS, PCOP, FACCC     Nirav Shah, MD, MSHP  Associate Professor of Medicine  Medical College of Wisconsin  Division of Hematology and Oncology  Milwaukee, Wisconsin    Kirollos Hanna, PharmD, BCPS, PCOP, FACCC  Assistant Professor of Pharmacy, Mayo Clinic  Director of Pharmacy  Minnesota Oncology   St. Paul, Minnesota    This project is made possible by funding and support provided by Eli Lilly and in collaboration with The Leukemia & Lymphoma Society. Resources Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  Relapsed/Refractory Mantle Cell Lymphoma Educational Video Series: Update on New Therapies: https://vimeo.com/942756449 BTK Inhibitors in MCL: https://vimeo.com/942755401 R/R MCL Case Studies: https://vimeo.com/942754652 BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2023-10/FSHP1_CART_Factsheet_June2022_rev.pdf   The CAR T-cell Therapy Process - https://www.lls.org/sites/default/files/2024-03/PS100_CART-CellTherapyProcessFlyer_0224.pdf   Patient-Caregiver CAR T-cell Therapy Facts - https://www.lls.org/sites/default/files/2024-04/FS27_CART_Fact_Sheet_0424_rev.pdf   Learn About CAR T-cell Therapy - https://www.lls.org/sites/default/files/2024-03/PS126_CART_ResourceCard_3_24.pdf    Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society  https://lls.org/sites/default/files/2023-08/FS4_Mantle_Cell_Facts_0423rev.pdf         

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA Recorded on June 6, 2024 Krish Patel, MD Director, Lymphoma Program Director, Hematologic Malignancies and Cellular Therapy Swedish Cancer Institute Seattle, WA Join us as Dr. Krish Patel from Swedish Cancer Institute explores mantle cell lymphoma, including the goals and latest advancements in treatment. He also provides insights on treating relapsed/refractory cases, discusses effective strategies for managing side effects, and highlights the importance of communication between patients and healthcare professionals for optimal care. Tune in to stay up to date on mantle cell lymphoma today!

In this week's episode we'll discuss the outcomes of younger patients with mantle cell lymphoma experiencing late relapse; learn more about mass spectrometry-based assessment of M-protein in peripheral blood during maintenance therapy in multiple myeloma and discuss in vivo CAR T-cell generation in non-human primates using lentiviral vectors.Featured Articles: Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD studyMass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy inmultiple myelomaIn vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand

Common adverse events associated with treatment of mantle cell lymphoma include gastrointestinal, hematologic, and cardiac toxicities. Proactive management of these toxicities and collaboration between members of the cancer care team, including pharmacists, are key to optimizing patient outcomes. In this episode, CANCER BUZZ speaks with Karen Fancher, PharmD, BCOP, clinical pharmacy specialist in oncology at University of Pittsburgh – Passavant Hospital, and Victoria Nachar, PharmD, BCOP, clinical pharmacist specialist in ambulatory hematology and adjunct clinical instructor at the University of Michigan, about strategies to address common adverse events experienced by patients with mantle cell lymphoma.  “There are some unique strategies using electronic resources if patients can be tech-savvy…We have some cool technology that use[s] text-message-based responses, where you can ask patients about side effects or vital signs. All they have to do is text a response, and it will automatically populate into the electronic medical record.”—Victoria Nachar, PharmD, BCOP   “I'm at a very small community practice…Institutions like Michigan are light years ahead of some of us in terms of patient-friendly communication strategies through technology…As those institutions perfect and work out the kinks, [the technology] is going to trickle down to those of us in the community setting. And I'm really excited to see how we can harness that technology for patients.”—Karen Fancher, PharmD, BCOP     Victoria Nachar, PharmD, BCOP  Clinical Pharmacist Specialist, Ambulatory Hematology  Adjunct Clinical Instructor  University of Michigan Rogel Cancer Center Ann Arbor, MI    Karen Fancher, PharmD, BCOP    Clinical Pharmacy Specialist, Oncology University of Pittsburgh Medical Center – Passavant Hospital Associate Professor of Pharmacy Practice   Duquesne University School of Pharmacy   Pittsburgh, PA    This video podcast was produced in partnership with The Leukemia & Lymphoma Society and made possible with support from Eli Lilly. Resources Cancer Diagnostics Education Program - ACCC Treatment for Relapsed/Refractory Mantle Cell Lymphoma Tip Sheet - ACCC  BTK Inhibitors Stretch Frontline Approaches in Mantle Cell Lymphoma – Targeted Oncology  Emerging Data Continue to Affect BTK Inhibitor Usage in Mantle Cell Lymphoma - OncLive  HCP Fact Sheet: Facts About CAR T-cell Therapy The CAR T-cell Therapy Process Patient-Caregiver CAR T-cell Therapy Facts Learn About CAR T-cell Therapy  Mantle Cell Lymphoma Facts for Patients and Caregivers -The Leukemia & Lymphoma Society

Featuring perspectives from Dr Andrew D Zelenetz, including the following topics: Follicular Lymphoma (0:00) Mantle Cell Lymphoma (30:29) Diffuse Large B-Cell Lymphoma (55:01) Hodgkin Lymphoma (1:12:25) CME information and select publications

Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPostConf24/Lymphoma).

Featuring perspectives from Dr Andrew M Evens and Dr Sonali M Smith, including the following topics:  Introduction: CD3-Based Bispecific Antibodies and the General Medical Oncologist: Lymphomas, Multiple Myeloma … and Solid Tumors? (0:00) Follicular and Mantle Cell Lymphoma (7:17) Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma (30:10) CME information and select publications   

Although strides have been made with Bruton tyrosine kinase (BTK) inhibitors and CAR-T cell therapy, relapse and resistance remain significant hurdles in treating patients with mantle cell lymphoma (MCL). The Lymphoma Research Foundation's 2023 MCL Scientific Consortium and Workshop addressed these complexities, aiming to dissect the intricate biology of MCL and propel progress towards a cure. CancerNetwork® spoke with leaders in the MCL field to better understand the aim of the consortium and the advancements they hope to see in the space. The journal ONCOLOGY® published these findings in the February 2024 issue. The interviews included Elias Campo, MD, PhD, research director and professor of anatomic pathology at the Hospital Clinic of the University of Barcelona; Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas, MD Anderson Cancer Center; Martin Dreyling, MD, PhD, professor of Medicine in the Department of Medicine and head of the Medical Clinic 3 at the University of Munich-Grosshadern in Germany; and Julie M. Vose, MD, MBA, Neumann M. and Mildred E. Harris Professor and division chief in the Division of Hematology at the University of Nebraska Medical Center and coeditor in chief of ONCOLOGY.  The consortium touched on t(11;14), which dysregulates cyclin D1 and fuels uncontrolled cell growth. Additionally, research presented at the consortium revealed other molecular pathways contributing to treatment resistance and relapse, highlighting the heterogeneous nature of the disease. This heterogeneity underscored the need for personalized treatment strategies and biomarker-based prognostics, a notion further emphasized by multiple findings on the predictive value of specific gene mutations. Beyond understanding the inner workings of MCL, presentations also focused on novel therapeutic avenues. Specifically, there were encouraging data on the potential of next-generation BTK inhibitors including acalabrutinib (Calquence) to overcome resistance. Challenges such as the limitations of current risk stratification models remain, underscoring the need for robust biomarkers to guide early interventions and optimize treatment selection. Additionally, the consortium featured a discussion on addressing a lack of diversity in clinical trial populations, which may help increase treatment access for those with various medical conditions. “…The patient population that has a disease is not always [represented] in the clinical trials. That's why it's important to be able to have a diversity of patients in clinical trials: to test these new therapies because [patients] may have other medical conditions that would change the outcome of trials and not be necessarily representative of the entire patient population with that disease,” Vose said. “It's important to try to advance the treatment of a very diverse patient population through these clinical trial mechanisms.”

This week's episode will be focusing on Mantle Cell Lymphoma. We will go over the important details on the presentation, diagnosis and treatment.

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on patient advocacy groups in hematology, efforts to reduce racial disparities in multiple myeloma clinical trials, real-world outcomes of novel agents in the community setting, and much more!

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!

In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK. Here are the abstracts that were discussed: Mantle Cell Lymphoma 1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper180069.html 2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)  https://ash.confex.com/ash/2023/webprogram/Paper191921.html Chronic Lymphocytic Leukemia 1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063 2. Ibrutinib retreatment in Phase 2 CAPTIVATE study: https://ash.confex.com/ash/2023/webprogram/Paper187128.html Hodgkin Lymphoma 1. S1826 outcomes in older adults:  https://ash.confex.com/ash/2023/webprogram/Paper180114.html Diffuse Large B-cell Lymphoma 1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper180381.html 2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2023/webprogram/Paper177588.html

In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 1. Glofitamab for Relapsed/Refractory DLBCL:https://pubmed.ncbi.nlm.nih.gov/36507690/ 2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:https://pubmed.ncbi.nlm.nih.gov/31451445/ 3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:https://pubmed.ncbi.nlm.nih.gov/36548927/ 4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:https://pubmed.ncbi.nlm.nih.gov/35803286/ 5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:https://pubmed.ncbi.nlm.nih.gov/35366963/ 6. Epcoritamab + R2 in high-risk follicular lymphoma:https://meetings.asco.org/abstracts-presentations/218265 7. Glofitamab in Mantle Cell Lymphoma:https://ashpublications.org/blood/article/140/Supplement%201/178/489039

In this episode, Ana Marin-Niebla, MD, PhD, and Stephan Stilgenbauer, MD, discuss key trial data on the use of BTK inhibitors in CLL and MCL throughout the past year, how these studies have impacted their practice, and what data they are looking forward to in the near future. The discussion includes analyses of: SHINE: First-Line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL TRIANGLE: Ibrutinib + Chemoimmunotherapy With or Without ASCT vs Chemoimmunotherapy Followed by ASCT in Younger Patients with Previously Untreated MCL ZUMA-2: Brexucabtagene Autoleucel in R/R MCL BRUIN: Pirtobrutinib for Previously Treated MCL GLOW: Fixed-Duration Ibrutinib + Venetoclax vs Chlorambucil + Obinutuzumab in Previously Untreated CLL FLAIR: Ibrutinib + Venetoclax vs FCR in Previously Untreated CLL ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL ALPINE: Zanubrutinib vs Ibrutinib in Previously Treated CLL BRUIN: Pirtobrutinib for Previously Treated CLLPresenters: Ana Marin-Niebla, MD, PhDHematology Consultant, Lymphoma UnitVall d'Hebron Institute of Oncology, Hematology DepartmentHospital Universitario Vall d'HebronBarcelona, SpainStephan Stilgenbauer, MDMedical Director Comprehensive Cancer Center UlmHead, Early Clinical Trials UnitHead, Division of CLL Dept. of Internal Medicine IIIUniversity Medical CenterUlm UniversityUlm, GermanyLink to full program: https://bit.ly/3MNaUri

In this week's episode, we discuss the findings from a phase 2 study of lenalinomide plus rituximab in elderly frail patients with DLBCL, learn more about platelet GP6-mediated neutrophil recruitment in early stages of acute lung injury, and discuss a newly identified isoform of the tyrosine kinase AXL, termed AXL3, in mantle cell lymphoma.

Featuring perspectives from Dr Toby A Eyre and Dr Brad S Kahl, including the following topics: Introduction: Mantle Cell Lymphoma (MCL) and the General Medical Oncologist (0:00) Sequencing of Therapy for MCL: 2009-2025 (11:19) Cases and Questions from the Community (36:44) Case: A man in his early 80s with relapsed/refractory MCL with “brain fog” on zanubrutinib — Zanetta S Lamar, MD (56:07) CME information and select publications

Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma.

Dr Toby A Eyre from the Oxford University Hospitals NHS Foundation Trust in Oxford, United Kingdom, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, discuss the management of relapsed/refractory mantle cell lymphoma. CME information and select publications here (https://www.researchtopractice.com/RRMCL2023)

Featuring a slide presentation and related discussion from Dr Michael Wang, including the following topics: Overview of Bruton tyrosine kinase (BTK) inhibitors and clinical data establishing the efficacy of these agents for mantle cell lymphoma (MCL) (0:00) Clinical investigation of ibrutinib in the front-line setting; results from the Phase III SHINE trial and voluntary market withdrawal of ibrutinib for MCL (4:36) Phase III TRIANGLE trial of ibrutinib combined with chemotherapy as upfront therapy for younger patients with MCL; role of autologous stem cell transplant (11:14) Acalabrutinib and zanubrutinib for the treatment of relapsed/refractory (R/R) MCL (14:16) Key findings from the BRUIN trial leading to the FDA approval of pirtobrutinib for R/R MCL (16:23) CME information and select publications

Featuring perspectives from Dr Michael Wang, including the following topics: Algorithm for observation versus initiation of therapy for newly diagnosed mantle cell lymphoma (MCL) (0:00) First- and second-line therapy approaches for MCL (7:26) Case: A 45-year-old woman with relapsed MCL receiving acalabrutinib who develops severe headaches (10:21) Current role of ibrutinib in the treatment of MCL; use of single-agent venetoclax and of zanubrutinib in the treatment algorithm (14:59) Case: A 68-year-old man presenting with an enlarged spleen, no lymphadenopathy and a white blood cell count of 300,000 is diagnosed with MCL (17:48) Case: A 71-year-old man with multiregimen-relapsed, nodular type MCL presents with lymphadenopathy and a 3-cm tumor near the mediastinum (22:38) Patient selection for chimeric antigen receptor T-cell therapy (25:59) Novel and investigational therapeutic approaches for MCL (30:11) Treatment approaches for other histological variants of MCL (39:00) CME information and select publications

Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love.

Featuring a discussion on BTK inhibitors for the management of mantle cell lymphoma with Dr Michael Wang, moderated by Dr Neil Love. CME information and select publications here (https://researchtopractice.com/OncologyTodayBTKInhibitorsMCL23).

Dr Ian W Flinn discusses the management of Hodgkin and non-Hodgkin lymphoma. CME information and select publications here (http://www.researchtopractice.com/MTPLymphoma23/)

In this episode, we delve into the management of newly diagnosed mantle cell lymphoma with Dr. Martin Dreyling. Here the shownotes:2:11 How to diagnose mantle cell lymphoma (MCL)?6:51 Clinical manifestations of mantle cell lymphoma7:52 How to manage leukemic variant of MCL? 12:08 Is Watch-and-Wait reasonable in selected cases of nodal MCL with low Ki-67?17:21 Overview on treatment of newly diagnosed MCL19:03 Are all cytarabine-based regimens for MCL created equally?  RCT of Autologous Transplantation in MCL: https://pubmed.ncbi.nlm.nih.gov/15591112/21:39 In a world without upfront ibrutinib access as per TRIANGLE trial, do all fit patients with MCL need consolidation with auto-transplant? 22:44 How to approach unfit patients with newly diagnosed MCL? RCT of bortezomib-based therapy (VR-CAP) in newly diagnosed MCL: https://pubmed.ncbi.nlm.nih.gov/25738670/24:57 SHINE Trial-RCT of Ibrutinib plus BR in newly diagnosed MCL: https://pubmed.ncbi.nlm.nih.gov/35657079/30:38 TRIANGLE Trial-RCT of upfront ibrutinib with or without auto-transplant in newly diagnosed MCL:https://ashpublications.org/blood/article/134/Supplement_1/2816/42350443:01: Does Allo-Transplant have any role in MCL?44:08: What are the likely next breakthroughs in newly diagnosed MCL space? 

After taking some time for reflection and healing, we are thrilled to announce the continuation of Gorge Real Estate Talk. As many of you are aware, our beloved host and dear friend, Kimberly Salvesen, passed away on January 1st, 2023 after a courageous battle with Mantle Cell Lymphoma. Despite her diagnosis, Kim's indomitable spirit fueled her passion for the podcast and the real estate market. Initially created to keep our community members informed about the current state of the real estate market, the podcast evolved into a platform to spotlight local businesses and community programs. In today's episode, our new host, Alisha Nightingale, chats with Rachel Broughton and Kim Chamness, the new owners of Windermere Real Estate Columbia River Gorge, about Kim's remarkable legacy and the seamless transition of ownership. Although Kim's loss remains a heavy burden on our hearts and minds, the Windermere family has come together in a beautiful way to keep her vision alive. During this episode, you will hear from some of Kim's closest friends and colleagues about her inspiring impact as a mentor, a friend, and a pioneer in the real estate industry. We hope this special episode will serve as a touching tribute to Kim Salvesen and her extraordinary life. Moving forward, we have lined up some incredible guests and exciting topics that we can't wait to share with you. We appreciate your unwavering support and look forward to continuing this journey together.   To learn more about Kim Salvesen and her incredible life's journey, please visit below.   https://www.columbiagorgenews.com/obituaries/obituary-kimberly-salvesen/article_ff07bc60-92be-11ed-b330-7b96ff7e530f.html